Blueprint Medicines Corporation Profile Avatar - Palmy Investing

Blueprint Medicines Corporation

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (S…
Biotechnology
US, Cambridge [HQ]

FA

Fundamental Analysis · Most Recent Quarter

It is important to understand the FA Algorithm and the criterias before valuing it as a top-tier resource.

Read Rationale
Framework:
Valuation 43% Somewhat Weak
Profitability n.A. n.A.
Fin. Growth 67% Positive
Leverage & Liquidity 17% Weak
Per Share Metrics 33% Weak
Fin. Health n.A. n.A.
Fundamentals

Valuation

Metric Q4 Q1 Δ in %
EV/EBITDA -42.22 -86.77 -61.01
Graham Fair Price 36.71 12.82 9.38
PEG -87.35 -0.09 0.73
Price/Book -55.56 19.11 43.00
Price/Cash Flow 13.87 -57.86 -67.18
Prices/Earnings 31.55 16.65 -12.66
Price/Sales -20.86 61.77 78.05
Price/FCF 13.87 -57.86 -67.18
Naive Interpretation member
01 - Valuation · Somewhat Weak
Fundamentals

Profitability

Metric Q4 Q1 Δ in %
Gross Profit Margin -5.98 0.92 0.98
Operating Margin 43.86 -0.82 -1.46
ROA -18.80 0.09 -0.11
ROE -0.85 0.29 -66.22
ROIC -0.13 -0.09 25.85
Naive Interpretation member
02 - Profitability · Not Interpreted
Fundamentals

Financial Growth

Metric Q4 Q1 Δ in %
Debt QOQ -0.23 5.15 -95.58
Dividends QOQ 0.00 0.00 0.00
EBIT QOQ 0.19 0.25 35.13
EPS QOQ 0.17 1.80 940.20
FCF QOQ 0.25 -0.23 -7.17
Revenue QOQ 0.27 0.34 23.39
Naive Interpretation member
03 - Financial Growth · Positive
Fundamentals

Leverage & Liquidity

Metric Q4 Q1 Δ in %
Assets Turnover n.A. n.A. n.A.
Days Inventory Outstanding (DIO) 1066.48 348.03 -67.37
Days Sales Outstanding (DSO) 54.00 56.23 4.11
Inventory Turnover 0.08 0.26 206.43
Debt/Capitalization 0.84 0.63 -25.62
Quick Ratio 3.51 3.43 -2.30
Naive Interpretation member
04 - Leverage & Liquidity · Weak
Fundamentals

Per Share Metrics

Metric Q4 Q1 Δ in %
Book Value 2.14 5.05 135.21
Cash 11.67 10.52 -9.85
Capex -0.08 -0.02 76.64
Free Cash Flow -1.37 -1.67 -21.37
Revenue 1.18 1.56 32.08
Naive Interpretation member
05 - Per Share Metrics · Weak
Fundamentals

Financial Health

Metric Q4 Q1 Δ in %
Current Ratio 3.76 3.76 -0.06
Debt/Assets n.A. n.A. n.A.
Debt/Equity n.A. n.A. n.A.
Net Debt/EBITDA -6.79 -6.55 3.51
Naive Interpretation Member
06 - Financial Health · Bad
End of BPMC's Analysis
CIK: 1597264 CUSIP: 09627Y109 ISIN: US09627Y1091 LEI: - UEI: -
Secondary Listings
BPMC has no secondary listings inside our databases.